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Patients (or Materials) and Methods: Male Wistar rats were used 
(340 ± 20 g) at standard conditions. Hypertension was induced by 
a previously described surgical method (PAGE), which was obtained 
with measurements HAS stable (plethysmographic method) from 
the seventh postoperative day, the eighth day began therapy OHB, 
for 5 days per week for 4 weeks. At the end of treatment, the 
rats were sacrificed getting heart; this was mounted on a system 
of isolated organ (Langendorff system), and it was stimulating to 
logarithmic doses of angiotensin II (Ang II) to measure variations in 
vascular reactivity associated with the RAS in coronary resistance 
arteries. The results are analized with 2 way ANOVA and post hoc 
Von Ferroni.
Results: The diastolic pressure measurement was obtained a pressure 
of 150 ± 15 mm Hg, consistent with the definition of hypertension. 
When analyzing perfusion pressure resistance in coronary arteries, 
the HBP group without treatment showed an increase in vascular 
reactivity compared with the healthy group. Whereas the HBP with 
HBO group no presented changes in vascular reactivity to any dose 
of Ang II, compared with healthy control group.
Conclusion: HBO therapy reduces vascular reactivity in coronary 
resistance arteries under Ang II stimulation in a model of hyperten-
sion of renal origin. This suggests that HBO could be used with 
hypertensive patients to reduce the development of heart disease and 
in another way it could help to improve the functionality of the heart 
and reduce the use of drugs in the HBP treatment.
Disclosure of Interest: None declared.
PP102—MoleCular doCkiNg reSearCh & 
iN-ViTro aNalySiS of NoVel NaTural aNd 
SyNTheTiC PTP 1B iNhiBiTorS aS PoTeNTial 
TheraPeuTiC TargeT for diaBeTeS MelliTuS
D. Ahmed*
Department of Pharmaceutical Sciences, Faculty of Health 
Sciences, SHIATS-Deemed University, Allahabad, India
Introduction: Augmented pervasiveness of type 2 diabetes mellitus 
and obesity has amplified the medical necessitate for new agents to 
treat these disease states. Both type 2 diabetes and obesity are con-
nected to the resistance to the hormones insulin and leptin. Protein 
tyrosine phosphatase 1B (PTP1B) has been shown to function as 
negative regulator of insulin signaling as well as leptin signal trans-
duction. This research exertion shows the molecular docking analysis 
of novel synthetically prepared compounds and new-fangled isolated 
natural PTP 1B inhibitors as novel target for type 2 diabetes.
Patients (or Materials) and Methods: Molegro Virtual Docker 
(MVD) has been used to dock novel natural PTP1B inhibitors with 
the Discovery Studio 3.0 visualizer.
Results: Molecular docking of novel natural PTP1B inhibitors 
showed some compounds with excellent dock score with greater 
binding affinity exhibiting pi-pi interactions
Conclusion: The plausible mechanism of action of various natural 
PTP1B inhibitors has been explained supported by in vitro experi-
mentation data. Traditional drugs with unknown mechanism of 
action were experimented for the PTP1B inhibitory activity and 
therefore are attention-grabbing biologically lead compounds.
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Introduction: Cardiac arrhythmia is 1 of the critical health condi-
tions. Clofibrate is a peroxisome proliferated-activator receptor-α 
(PPAR-α ) agonist that is widely used for reducing triglycerides in 
hyperlipidemic patients. Because this drug has showed several ben-
eficial effects in relief of some cardiovascular diseases, the aim of the 
present study was to evaluate antiarrhythmic effects of clofibrate on 
ouabain-induced arrhythmia in rats.
Patients (or Materials) and Methods: Twenty male rats weighing 
220 to 250 g were divided into 2 equal groups randomly. Group 1 
(treatment) received clofibrate (300 mg/kg) solved in olive oil (1 mL/
kg) once daily for 14 days intraperitoneally. Group 2 (vehicle control) 
only received olive oil (1 mL/kg) once daily for 14 days intraperito-
neally. After induction of anesthesia, heart was rapidly removed and 
the atria were immersed in a tissue bath containing modified Krebs 
solution andattached to isometric force transducer of PowerLab 
machine. Time of onset of arrhythmia and asystole, atrial beating 
rate, and contractile force were recorded and analyzed statistically 
with paired and Student’s t test in treatment and control groups.
Results: Clofibrate significantly postponed time of onset of arrhyth-
mia (23.57 [4.69] minutes) rather than control group (2.04 [0.27] 
minutes; P = 0.024). A significant increase in the onset time of asys-
tole in treatment group (66.19 [12.33] minutes) was observed, while 
this time for control group was 22.77 (7.17) (P = 0.004). Incubation 
of ouabain increased the atrial beating rate in control group signifi-
cantly (P = 0.022), while it does not show such effect in treatment 
group (P = 0.845). Incubation of ouabain had no effects on con-
tractile force in control and treatment groups (P = 0.063 and P = 
0.539, respectively).
Conclusion: Based on the findings, clofibrate may possess poten-
tials to reduce some kinds of cardiac arrhythmias. Further studies 
especially on in vivo arrhythmial models can more elucidate these 
beneficial effects of this drug.
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Introduction: The aim of this study was to investigate whether acti-
vation of the nuclear enzyme poly(ADP-ribose) polymerase (PARP) 
contributes to the development of endothelin-1 (ET-1)-induced 
endothelial dysfunction.
Patients (or Materials) and Methods: To evaluate vascular reactivity, 
isometric tension studies were performed in response to vasodilator 
agents, acetylcholine (ACh) and sodium nitroprusside (SNP), and con-
strictor agents, potassium chloride (KCl) and phenylephrine (Phe), 
in rat thoracic aorta rings incubated with or without ET-1(10-3 M, 
18 hours). To investigate mechanisms of ET-1 action, additional sets 
of experiments involving rings incubation with ET-1 alone or with 
addition of polyethylene glycol–superoxide dismutase (PEG-SOD, a 
cell permeable superoxide radical scavenger, 41 U/mL) plus apocynin 
(a NADPH oxidase inhibitor, 300 µM), and PJ34 (an inhibitor of 
polyADP-ribose polymerase, 3 × 10-6 M) for 18 hours, and both 
relaxant and constrictor responses were evaluated. Moreover, PARP-1 
and poly(ADP-ribose) (PAR, an end-product of PARP activity) expres-
sions were evaluated by Western blot and immunohistochemistry.
Results: The results of this study demonstrated that incubation of 
thoracic artery rings with ET-1 (10-3 M, 18 hours) resulted in sig-
nificant inhibition of response to ACh (an endothelium-dependent 
vasodilator) while SNP (an endothelium-independent vasodilator)-
